Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTurbo
NCT05340270Phase 2Active, not recruiting
- Sponsor
- Guangxi Medical University
- Start
- Jul 2022
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, randomised trial in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Guangxi Medical University. Primary endpoint: Failure-free survival at 24 months. Started Jul 2022; status: active, not recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05340270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340270.